Spesolimab

(Spevigo®)

Spesolimab

Drug updated on 11/15/2023

Dosage FormInjection (intravenous; 450 mg/7.5 mL (60 mg/mL))
Drug ClassInterleukin-36 receptor antagonists
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of generalized pustular psoriasis flares in adults.

Product Monograph / Prescribing Information

Document TitleYearSource
Spevigo (spesolimab-sbzo) Prescribing Information. 2022Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT

Systematic Reviews / Meta-Analyses